AstroStem vs Laromestrocel

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Alzheimer's Disease

Shared mechanism: Mesenchymal stem cell therapy · full Alzheimer's Disease pipeline

AstroStem

Developed by Nature Cell Co., Ltd. and partners

Phase 2 in Alzheimer's DiseaseCell therapy (autologous adipose MSC)
Weak signal

NCT03117738 · Phase 1/2 · completed

This trial was randomized and triple-blinded with a placebo control, which is a strong design foundation, but it enrolled only 21 participants (11 vs 10, with substantial dropout leaving just 7 per arm for the cognitive endpoint), making it severely underpowered. The primary cognitive endpoint (ADAS-Cog change) numerically favored placebo over AstroStem, and no p-value or confidence interval was reported for either primary outcome, so the primary comparison cannot be called a success for the drug.

Reported efficacy

Treatment Related Adverse Events (30 Weeks); ADAS-Cog (Alzheimer's Disease Assessment Scale-cognitive Subscale) (Baseline and 30 Weeks): ADAS-Cog change at Week 30: 5.9 (SD 6.8) AstroStem vs 3.0 (SD 5.4) placebo; n=7 vs 7. (unclear)

Result source: NCT03117738

Laromestrocel · Lomecel-B

Developed by Longeveron (NASDAQ: LGVN)

Phase 2 in Alzheimer's Diseasecell therapy (allogeneic MSC)
Weak signal

NCT05233774 · Phase 2 · completed

This trial was randomized, blinded, and placebo-controlled, but it enrolled only 50 patients and was designed primarily to test safety rather than a clinical outcome; cognitive measures were assessed only as secondary endpoints. The safety objective was met, but the small size and safety-focused design mean this trial does not by itself demonstrate a clinical benefit. Its registered primary outcome on ClinicalTrials.gov is "Primary Endpoint 1: Safety - SAEs and AEs" (with 1 other safety or dose-finding measure). Its registered primary outcomes are safety, tolerability or dose-finding measures only, so the evidence grade is capped at weak.

Reported efficacy

Primary Endpoint 1: Safety - SAEs and AEs (41 weeks); Primary Endpoint 2: Safety - Imaging (41 weeks): Primary safety endpoint (SAEs/AEs through 41 weeks): no infusion-related reactions, no ARIA, no deaths in any group; 1 SAE within 30 days post-infusion in each of the three Lomecel-B dose groups (3 total) versus 0 SAEs in the placebo group. (not_applicable)

Result source: NCT05233774

Results for Alzheimer's Disease

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointAstroStemLaromestrocel
CDR-SB, change1.3 vs 0.9+0.4 vs placebowk 30 · n 7NCT03117738—Not reported
ADAS-Cog11, change—Not reported—Not reported
ADCS-ADL, change-4.4 vs -4.7+0.3 vs placebowk 30 · n 7NCT03117738—Not reported
MMSE, change-3.4 vs -1.4−2 vs placebowk 30 · n 7NCT03117738—Not reported
Amyloid PET, change (centiloids)—Not reported—Not reported

CDR-SB, change

AstroStem
1.3 vs 0.9+0.4 vs placebowk 30 · n 7NCT03117738
Laromestrocel
—Not reported

ADAS-Cog11, change

AstroStem
—Not reported
Laromestrocel
—Not reported

ADCS-ADL, change

AstroStem
-4.4 vs -4.7+0.3 vs placebowk 30 · n 7NCT03117738
Laromestrocel
—Not reported

MMSE, change

AstroStem
-3.4 vs -1.4−2 vs placebowk 30 · n 7NCT03117738
Laromestrocel
—Not reported

Amyloid PET, change (centiloids)

AstroStem
—Not reported
Laromestrocel
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Laromestrocel: no structured comparison results are available for Alzheimer's Disease.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. AstroStem: 3 of 4 rows · Laromestrocel: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricAstroStem
Dropout rate
36.4%
NCT03117738 · Phase 1/2 · monotherapy · Alzheimer's Disease · phase 1/2
Discontinued due to AEs
—
NCT03117738 · Phase 1/2 · monotherapy · Alzheimer's Disease · phase 1/2
Serious AEs
27.3%
NCT03117738 · Phase 1/2 · monotherapy · Alzheimer's Disease · phase 1/2
Most frequent reported AEs
abnormal loss of weight 9.1% (placebo 0%)
dehydration 9.1% (placebo 10%)
dysphagia 9.1% (placebo 0%)
NCT03117738 · Phase 1/2 · monotherapy · Alzheimer's Disease · phase 1/2

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

AstroStem

ADAS-Cog 5.9 vs 3 placebo score @ 30wk
absolute change · score
NCT03117738 · Phase 1/2 · monotherapy · Alzheimer's Disease · phase 1/2
MMSE -3.4 vs -1.4 placebo score @ 30wk
absolute change · score
NCT03117738 · Phase 1/2 · monotherapy · Alzheimer's Disease · phase 1/2
CDR-SB 1.3 vs 0.9 placebo score @ 30wk
absolute change · score
NCT03117738 · Phase 1/2 · monotherapy · Alzheimer's Disease · phase 1/2
NPI -1.4 vs -5.7 placebo score @ 30wk
absolute change · score
NCT03117738 · Phase 1/2 · monotherapy · Alzheimer's Disease · phase 1/2
GDS -0.3 vs 0.3 placebo score @ 30wk
absolute change · score
NCT03117738 · Phase 1/2 · monotherapy · Alzheimer's Disease · phase 1/2
ADCS-ADL -4.4 vs -4.7 placebo score @ 30wk
absolute change · score
NCT03117738 · Phase 1/2 · monotherapy · Alzheimer's Disease · phase 1/2

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: AstroStem's landscape · Laromestrocel's landscape